Related Experiment Video
Updated: Jul 14, 2026

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos
Published on: March 21, 2021
Sarcopenia does not affect total liver function measured using technetium-99m mebrofenin hepatobiliary scintigraphy
Pieter Arntz1, Pim Olthof2,3, Fadi Rassam2
1Cancer Center Amsterdam, Amsterdam UMC, Department of Surgery, University of Amsterdam, VUMC, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands. p.j.arntz@amsterdamumc.nl.
Background:
Hepatobiliary scintigraphy (HBS) using technetium-99m mebrofenin is used to preoperatively estimate risk of adverse outcomes after major liver resections. Sarcopenia has been independently associated with adverse outcomes after surgery. This retrospective cohort study aimed to correlate patient- and disease-related factors, including sarcopenia, with total liver function (TLF) through HBS analysis.
Results:
During the study period, 346 patients underwent HBS to quantify TLF. The median TLF was 15.0 (12.1-16.7) %/min. Body composition parameters were not correlated to TLF. Older age, a diagnosis of hepatocellular carcinoma, underlying cirrhosis and high serum bilirubin levels were independently correlated with decreased TLF. In contrast, the absence of underlying liver disease and overall good health were independently correlated with higher TLF. Sarcopenia was not correlated with TLF.
Conclusion:
Sarcopenia does not impact TLF. Total liver function measured with HBS is negatively correlated with older age, a diagnosis of hepatocellular carcinoma, underlying cirrhosis and serum bilirubin level.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET